Free Content
Investing is complex and difficult. The "Big Lie" of the last decade said investing was an easy hobby. To be successful over time requires hard work and help from people you trust. We founded BSR in order to help investors. This no-charge area of our site is but one of the ways we fulfill this mission.
We have samples of our research so you can "try before you buy", so to speak. We don't offer a free trial out of respect for those who subscribe to our research. We also don't offer a wide variety of free samples for the same reason. If you are interested in subscribing, but don't want to make a big commitment until you read more, you can either buy a single issue of Biotech Monthly or take advantage of our inexpensive introductory subscription.
We have samples of our research so you can "try before you buy", so to speak. We don't offer a free trial out of respect for those who subscribe to our research. We also don't offer a wide variety of free samples for the same reason. If you are interested in subscribing, but don't want to make a big commitment until you read more, you can either buy a single issue of Biotech Monthly or take advantage of our inexpensive introductory subscription.
BSR Alert samples
BSR Alerts cover breaking news in the companies we cover. Any time a company releases news we believe could use some additional commentary, we'll publish a BSR Alert. We typically average 100-200 Alerts per year.
We've prepared a few samples of our Alerts so you can see for yourself what they are like. Please note the dates for each of these Alerts. All of the research on these companies have been updated since they were published.
The first sample Alert is a preview of pivotal data from Dendreon's (DNDN) prostate cancer drug Provenge. We used the Alert to construct a tool to help Subscribers interpret the data and predict Wall Street's reaction. As with all of our research, the Alert is in PDF format. Make sure you have a current copy of the free Acrobat Reader, then click here to access this free sample.
Scientific conferences are where the big news happens in the biotech space. BSR provides big value for our Subscribers by attending many of these conferences during the year. This sample Alert from the American Society of Hematology (ASH) conference highlights data from ImmunoGen (IMGN) and Seattle Genetics (SGEN). As with all of our research, the Alert is in PDF format. Make sure you have a current copy of the free Acrobat Reader, then click here to access this free sample.
Biotech science can be pretty dense sometimes, particularly around the design of clinical trials. In 2009, Oncolytics Biotech (ONCY) described to our Research Team the particulars of their Phase III pivotal trial for their cancer drug Reolysin. This sample shows the kind of descriptive commentary and analysis we produce on clinical trials designs. As with all of our research, the Alert is in PDF format. Make sure you have a current copy of the free Acrobat Reader, then click here to access this free sample.
We've prepared a few samples of our Alerts so you can see for yourself what they are like. Please note the dates for each of these Alerts. All of the research on these companies have been updated since they were published.
The first sample Alert is a preview of pivotal data from Dendreon's (DNDN) prostate cancer drug Provenge. We used the Alert to construct a tool to help Subscribers interpret the data and predict Wall Street's reaction. As with all of our research, the Alert is in PDF format. Make sure you have a current copy of the free Acrobat Reader, then click here to access this free sample.
Scientific conferences are where the big news happens in the biotech space. BSR provides big value for our Subscribers by attending many of these conferences during the year. This sample Alert from the American Society of Hematology (ASH) conference highlights data from ImmunoGen (IMGN) and Seattle Genetics (SGEN). As with all of our research, the Alert is in PDF format. Make sure you have a current copy of the free Acrobat Reader, then click here to access this free sample.
Biotech science can be pretty dense sometimes, particularly around the design of clinical trials. In 2009, Oncolytics Biotech (ONCY) described to our Research Team the particulars of their Phase III pivotal trial for their cancer drug Reolysin. This sample shows the kind of descriptive commentary and analysis we produce on clinical trials designs. As with all of our research, the Alert is in PDF format. Make sure you have a current copy of the free Acrobat Reader, then click here to access this free sample.
BSR's Biotech Monthly samples
In addition to the 100-200 BSR Alerts we publish each year, we also publish Biotech Monthly at the
end of each month. We use this research publication to update thecompanies in our coverage universe, debut new
coverage, and communicate macro-level issues we believe are important to biotech investors. Each issue ranges from 30-50 pages.
April 2009 - Calling the bottom
We've been doing this for over a decade now and have learned when markets are terrible, play small. Not all of our Biotech Monthly issues initiate coverage on new companies. Sometimes we can't find new companies we think are any good or, in bad market, whose price will go up. In this issue, our Main Story is about the macro market. We called a bottom in biotech. And while you can see we didn't think at the time the remainder of 2009 was going to be as relentlessly up, we did get the initial timing correct. As with all of our research, the Alert is in PDF format. Make sure you have a current copy of the free Acrobat Reader, then click here to access this free sample.
July 2006 - Dynavax
Our first sample issue comes from July 2006. In it we debut our coverage on Dynavax (DVAX). The issue is a good cross-section of the type of work we include in each issue of Biotech Monthly. Please recognize we've updated all the opinions contained in this issue since the time it was published. As with all of our research, the Alert is in PDF format. Make sure you have a current copy of the free Acrobat Reader, then click here to access this free sample.
April 2002 - Esperion
Our second sample issue is much older, but it has proved so popular over the years we couldn't imagine not including it. It is our April 2002 issue of Biotech Monthly adding on to our initial coverage of Esperion. At the time it was written, HDL-directed therapy was relatively new and the company was trading for less than $6. A little over a year later, the company was acquired by Pfizer (PFE) for $23/share. The reason this issue is so popular is it is among the best, if not the best, lay description of the Reverse Lipid Transport process that allows investors to delineate between HDL therapies that will work and those that will not. It was also our first detailed criticism of CETP-inhibitors. Keep in mind this was published in 2002 and our research products have changed considerably since then. We've also published thousands of pages of updated research on the companies mentioned within the issue. As with all of our research, the Alert is in PDF format. Make sure you have a current copy of the free Acrobat Reader, then click here to access this free sample.
April 2009 - Calling the bottom
We've been doing this for over a decade now and have learned when markets are terrible, play small. Not all of our Biotech Monthly issues initiate coverage on new companies. Sometimes we can't find new companies we think are any good or, in bad market, whose price will go up. In this issue, our Main Story is about the macro market. We called a bottom in biotech. And while you can see we didn't think at the time the remainder of 2009 was going to be as relentlessly up, we did get the initial timing correct. As with all of our research, the Alert is in PDF format. Make sure you have a current copy of the free Acrobat Reader, then click here to access this free sample.
July 2006 - Dynavax
Our first sample issue comes from July 2006. In it we debut our coverage on Dynavax (DVAX). The issue is a good cross-section of the type of work we include in each issue of Biotech Monthly. Please recognize we've updated all the opinions contained in this issue since the time it was published. As with all of our research, the Alert is in PDF format. Make sure you have a current copy of the free Acrobat Reader, then click here to access this free sample.
April 2002 - Esperion
Our second sample issue is much older, but it has proved so popular over the years we couldn't imagine not including it. It is our April 2002 issue of Biotech Monthly adding on to our initial coverage of Esperion. At the time it was written, HDL-directed therapy was relatively new and the company was trading for less than $6. A little over a year later, the company was acquired by Pfizer (PFE) for $23/share. The reason this issue is so popular is it is among the best, if not the best, lay description of the Reverse Lipid Transport process that allows investors to delineate between HDL therapies that will work and those that will not. It was also our first detailed criticism of CETP-inhibitors. Keep in mind this was published in 2002 and our research products have changed considerably since then. We've also published thousands of pages of updated research on the companies mentioned within the issue. As with all of our research, the Alert is in PDF format. Make sure you have a current copy of the free Acrobat Reader, then click here to access this free sample.
We see our mission at BSR as including a large portion of investor education. Take a look at the following items and see if they help you become a better investor.
Long Term Investor Worksheet
Downloaded by thousands and thousands of investors since it was created in the late 1990s, our e-mail indicates those who follow this worksheet are considerably more likely to avoid significant portfolio losses. Based on the simple, but rarely followed idea that you should decide why to sell a stock before you ever purchased it, this worksheet help you make smart investment decisions. People have written us saying they force their stockbroker to fill it out each time he/she pitches a stock for their portfolio.
Minyanville
Minyanville.com is a great site for experienced investors who want no-nonsense, no-hype commentary on the market. Minyanville was founded by former Cramer/Berkowitz head trader Todd Harrison. BSR's CEO David Miller has been writing regularly for Minyanville since 2004. Below appear a selection of freely-available articles biotech investors will find interesting.
Death of the Blockbuster Drug - Penned in 2004, this describes a developing paradigm shift in drug development.
Are drugs safe? - There is no such thing as a safe drug. Drug approval is about balancing risk and benefit.
Wrong end of the telescope - Warns against deferring to the 'sky is falling' mentality of macro market bears.
Five rules - Five important rules for all biotech investors.
Clinical trial basics - Explaining the different clinical trial phases.
Making sense of FDA designations - Orphan, accelerated, Subpart H defined here.
The Age of the SPA - The most important development out of the FDA in the early "naughts".
Understanding the Science Behind Cancer - A layperson's primer on tumor antigens and active cancer immunotherapy.
The complete collection of David's Minyanville writings.
Long Term Investor Worksheet
Downloaded by thousands and thousands of investors since it was created in the late 1990s, our e-mail indicates those who follow this worksheet are considerably more likely to avoid significant portfolio losses. Based on the simple, but rarely followed idea that you should decide why to sell a stock before you ever purchased it, this worksheet help you make smart investment decisions. People have written us saying they force their stockbroker to fill it out each time he/she pitches a stock for their portfolio.
Minyanville
Minyanville.com is a great site for experienced investors who want no-nonsense, no-hype commentary on the market. Minyanville was founded by former Cramer/Berkowitz head trader Todd Harrison. BSR's CEO David Miller has been writing regularly for Minyanville since 2004. Below appear a selection of freely-available articles biotech investors will find interesting.
Death of the Blockbuster Drug - Penned in 2004, this describes a developing paradigm shift in drug development.
Are drugs safe? - There is no such thing as a safe drug. Drug approval is about balancing risk and benefit.
Wrong end of the telescope - Warns against deferring to the 'sky is falling' mentality of macro market bears.
Five rules - Five important rules for all biotech investors.
Clinical trial basics - Explaining the different clinical trial phases.
Making sense of FDA designations - Orphan, accelerated, Subpart H defined here.
The Age of the SPA - The most important development out of the FDA in the early "naughts".
Understanding the Science Behind Cancer - A layperson's primer on tumor antigens and active cancer immunotherapy.
The complete collection of David's Minyanville writings.